←Geriatric Patients
Study register · detail Prospektive Beobachtungsstudie · Geriatric Patients · 2023

Medical Cannabis Is Not Associated with a Decrease in Activities of Daily Living in Older

Abuhasira et al. ·Biomedicines Impact 4.3
Mixed GRADE Low 0 citations
Samplen = 119 Pat.
Durationsix months
EndpointADL score
Blindingn.a.
DesignProspektive Beobachtungsstudie
Cannabinoidvollspektrum
Key finding

Medical cannabis did not lead to a deterioration in ADL functionality, but showed adverse events in 36% of patients.

Summary

Prospective study ≥65 years (n=119, age 79,3±8,5, 62,2% female), cannabis treatment over 6 months; ADL score remained stable (4,4±1,8 vs. 4,5±1,8, p=0,27), IADL improved (4,1±2,6 vs. 4,7±3,0, p=0,02). 36,1% adverse events, 1,7% required medical intervention.

P
PopulationOlder adults (≥65 years) starting medical cannabis therapy (mainly chronic non-oncological pain), n=119, mean age 79,3 years
I
InterventionHerbal medical cannabis, various indications, in a specialized geriatric clinic (2018–2020)
O
OutcomeADL score before vs. after treatment: 4,4 ± 1,8 vs. 4,5 ± 1,8 (p=0,27); IADL score: 4,1 ± 2,6 vs. 4,7 ± 3,0 (p=0,02); 43 (36,1%) adverse events, 2 (1,7%) requiring medical care
Confidence in the evidence
Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Abuhasira R, Schwartz L, Novack V
DOI 10.3390/biomedicines11102697↗
Design: Prospektive Beobachtungsstudie
Share
Indication
Further studies on Geriatric Patients
All studies →
A Ceolin et al. · 2024 · The journal of nutrition, health & aging
4 citations
The potential of cannabinoids in managing cancer-related anorexia in older adults: a systematic review of the literature.
Mixed Systematic Review

Systematische Review zu Cannabinoiden bei Tumor-assoziierter Anorexie älterer Erwachsener; k=6 Studien (5 RCTs, 1 prospektive Studie), n=869 Teilnehmende (2002-2019). Megestrol 800 mg/d wirksamer als Dronabinol 2,5 mg 2×/d für Appetit. Nabilone 1,0 mg/d über 8 Wochen: signifikanter Anstieg Kalorienaufnahme und Kohlenhydratkonsum vs. Placebo. THC 5-10 mg/d: Gewichtszunahme ≥10% bei 17,6% der Patienten, verbesserte Chemosensorik und Appetit bei THC 2,5 mg vs. Placebo. Keine schwerwiegenden Nebenwirkungen berichtet.

10.1016/j.jnha.2024.100299 View study →
A Rosenberg et al. · 2026 · The American journal of geriatric psychiatry
3 citations
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.
Clear benefit RCT

n=75 Alzheimer-Patienten mit Agitation (NPI-C A/A ≥4), randomisiert doppelblind placebokontrolliert; Dronabinol (THC) bis 10 mg/Tag vs. Placebo über 3 Wochen (5 akademische Zentren, USA). Pittsburgh Agitation Scale (PAS): signifikant stärkere Abnahme unter Dronabinol (Differenz –0,74/Woche, SE 0,3, p=0,015, Effektgröße 0,53). NPI-C A/A Differenz –1,26 (SE 0,67, p=0,094). Keine erhöhte Intoxikation; Somnolenz als einzige signifikante Nebenwirkung. Adjunktives Dronabinol sicher und klinisch wirksam bei Agitation bei Alzheimer-Demenz.

10.1016/j.jagp.2025.10.011 View study →
A Pisani et al. · 2021 · Drugs & Aging
19 citations
Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.
Mixed Systematische Review und Meta-Analyse

SR und Meta-Analyse (k=38 Studien, N=2.341, Durchschnittsalter 63,2 Jahre); THC: Inzidenzrate (IR) aller UAW 122,18 (95%-KI 38,23–253,56), schwere UAW IR=0; CBD: IR aller UAW 111,91 (95%-KI 1,24–495,93), keine schweren UAW; THC:CBD-Kombination: schwere UAW IR 21,32 (95%-KI 0,18–93,26) — Cannabinoide insgesamt gut verträglich bei Erwachsenen >50 Jahre.

10.1007/s40266-021-00882-2 View study →

The impediment to action advances action. — Marcus Aurelius